Literature DB >> 8248481

Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome.

R Parshad1, F M Price, K F Pirollo, E H Chang, K K Sanford.   

Abstract

Noncancerous skin fibroblasts from six family members with Li-Fraumeni syndrome, five with cancer of diverse tissue origin and one with a premalignant neoplasm, showed a high frequency of chromatid aberrations, 94 to 119 breaks and 58 to 95 gaps per 100 metaphase cells arrested with colcemid 0.5 to 1.5 h after X irradiation (1.75 x 10(-2) C/kg). This response results from deficient repair of the radiation-induced DNA damage. In contrast, skin fibroblasts from two unrelated normal controls and a spouse showed 19 breaks and 17 to 19 gaps per 100 cells. Whereas all six members of the cancer-prone family had a radioresistant phenotype, only four had an inherited p53 mutation. Fibroblasts from a radioresistant family member showed the same extent of chromatid damage directly (0 to 0.5 h) after G2-phase X irradiation as those from the radiosensitive control spouse. We conclude, therefore, that radiosensitivity, as determined by cell killing in asynchronous populations of skin fibroblasts, is unrelated to chromosomal sensitivity to G2-phase X irradiation. However, the persistence of a high frequency of chromatid breaks and gaps at 0.5 to 1.5 h after G2-phase X irradiation, a manifestation of deficient DNA repair, is associated with proneness to cancer in this family.

Entities:  

Mesh:

Year:  1993        PMID: 8248481

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  10 in total

Review 1.  Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review.

Authors:  Mohamad Farid; Joanne Ngeow
Journal:  Oncologist       Date:  2016-07-08

2.  Rothmund-Thomson syndrome: two case reports show heterogeneous cutaneous abnormalities, an association with genetically programmed ageing changes, and increased chromosomal radiosensitivity.

Authors:  B Kerr; G S Ashcroft; D Scott; M A Horan; M W Ferguson; D Donnai
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

Review 3.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Cell cycle control, checkpoint mechanisms, and genotoxic stress.

Authors:  R E Shackelford; W K Kaufmann; R S Paules
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

5.  Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: a test for predisposition?

Authors:  D Scott; J B Barber; E L Levine; W Burrill; S A Roberts
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

6.  Deficient DNA repair capacity, a predisposing factor in breast cancer.

Authors:  R Parshad; F M Price; V A Bohr; K H Cowans; J A Zujewski; K K Sanford
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

7.  The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations.

Authors:  J M Boyle; A Spreadborough; M J Greaves; J M Birch; J M Varley; D Scott
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

8.  Sarcoma risk after radiation exposure.

Authors:  Amy Berrington de Gonzalez; Alina Kutsenko; Preetha Rajaraman
Journal:  Clin Sarcoma Res       Date:  2012-10-04

9.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.

Authors:  K J Williams; J Heighway; J M Birch; J D Norton; D Scott
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

Authors:  R Mirzayans; R A Aubin; W Bosnich; W A Blattner; M C Paterson
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.